Alternate day fasting for weight loss, weight maintenance, and cardio-protection
隔日禁食有助于减肥、维持体重和保护心脏
基本信息
- 批准号:8021545
- 负责人:
- 金额:$ 40.27万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2011
- 资助国家:美国
- 起止时间:2011-06-01 至 2015-01-31
- 项目状态:已结题
- 来源:
- 关键词:AddressAdherenceAdipocytesAttitudeBehavioralBlood PressureBody WeightBody Weight decreasedBody fatC-reactive proteinCaloric RestrictionCell SizeCell physiologyCholesterolCognitiveCoronary heart diseaseDataDietDiet therapyEatingEating BehaviorEnergy IntakeFastingFoodFutureHormonesIndividualInterventionLinkLipidsLow-Density LipoproteinsObesityOverweightParticle SizePhasePilot ProjectsPlasmaProtocols documentationRandomizedRegimenRelative (related person)ResearchRiskRisk FactorsRisk ReductionSelf EfficacyTestingVascular DiseasesWeightWeight Gainarmdietary restrictiondisorder riskexperiencefeedingheart disease preventionheart disease riskimprovedinsightnutritionpreventresponserestrainttreatment durationweight maintenance
项目摘要
DESCRIPTION (provided by applicant): Overweight and obese individuals are at increased risk for coronary heart disease (CHD). Losing weight by means of dietary restriction greatly reduces vascular disease risk. The most common dietary restriction protocol implemented is daily calorie restriction (CR). Another dietary restriction regimen employed, although far less commonly, is alternate day modified fasting (ADMF). ADMF involves a "feed day" where food is consumed ad-libitum, alternated with a "fast day", where food intake is partially reduced. Results from our 12- week pilot study show that adherence to ADMF exceeds that of CR after 8 weeks of treatment. This increased adherence to ADMF results in greater weight loss, which produces more pronounced improvements in CHD risk. What has yet to be determined is whether adherence to ADMF remains near maximal for longer treatment durations (24 weeks), and if this improved adherence results in greater reductions in body weight and CHD risk, versus CR. Once weight loss is achieved, weight maintenance is extremely important as CHD risk can increase if weight is regained. Whether ADMF is an effective strategy for weight maintenance remains unknown. Accordingly, the aims of this proposal are: Aim 1: To establish that adherence to ADMF is greater than that of CR during a 24-week intervention period and to determine if increased adherence to ADMF results in greater weight loss; Aim 2: To establish that greater reductions in body weight by ADMF over a 24-week period will result in greater improvements in traditional CHD risk parameters (blood pressure, plasma lipid levels, cholesterol synthesis rate, LDL particle size, and CRP) and emerging CHD risk parameters (fat cell- derived hormones, body fat distribution, and fat cell size) in comparison to CR; and Aim 3: To establish that ADMF is an effective diet therapy to maintain weight loss and sustain improvements in CHD risk indicators, and to compare changes in cognitive and behavioral components of eating between ADMF and CR subjects. A 52-week randomized, controlled, parallel-arm feeding trial will be implemented to test these objectives. The trial will be divided into 3 consecutive intervention periods: (1) 4-week baseline; (2) 24-week weight loss with food provided; and (3) 24-week weight maintenance with no food provided. Overweight and obese subjects (n = 90) will be randomized to 1 of 3 groups: (1) ADMF, 75% energy restriction on the "fast day" and ad libitum fed on the "feed day"; (2) CR, 25% restriction everyday; or 3) control, 100% energy intake every day. During the weight maintenance phase, ADMF subjects will consume 25% of their energy needs on the "fast day" and 175% of their needs on the "feed day", while CR and control subjects will consume 100% of their needs every day. Our findings will show that ADMF can be implemented as an alternative to CR to help overweight and obese individuals lose weight, maintain weight loss, and sustain reductions in CHD risk. This study will also generate insights into the specific behavioral changes that occur with ADMF that explain why ADMF is a successful diet strategy for weight maintenance.
PUBLIC HEALTH RELEVANCE: The proposed research will demonstrate that alternate day modified fasting (ADMF) is a suitable alternative to daily calorie restriction (CR) for weight loss, weight maintenance, and heart disease prevention. Since many overweight and obese individuals find it difficult to adhere to daily CR, this diet option may improve adherence with these dietary restriction protocols. This, in turn, will allow a greater percent of the overweight and obese population to lose weight, maintain weight loss, and prevent future occurrences of coronary heart disease.
描述(由申请人提供):超重和肥胖个体患冠心病(CHD)的风险增加。通过饮食限制减肥可以大大降低血管疾病的风险。最常见的饮食限制方案是每日卡路里限制(CR)。另一种饮食限制方案是隔日改良禁食(ADMF),尽管不太常见。ADMF涉及“进食日”,在该日,食物自由进食,与“禁食日”交替,在该日,食物摄入量部分减少。我们12周的初步研究结果表明,治疗8周后,ADMF的依从性超过CR。这种增加的ADMF依从性导致更大的体重减轻,从而产生更明显的CHD风险改善。目前尚不确定的是,与CR相比,ADMF的依从性是否在更长的治疗持续时间(24周)内保持接近最大值,以及这种依从性的改善是否会导致体重和CHD风险的更大降低。一旦体重减轻,体重维持是非常重要的,因为如果体重恢复,CHD风险会增加。ADMF是否是维持体重的有效策略仍不清楚。因此,本提案的目的是:目的1:确定在24周干预期间,ADMF依从性大于CR依从性,并确定ADMF依从性的增加是否会导致更大的体重减轻;目的2:确定ADMF在24周内更大程度地降低体重将导致传统CHD风险参数的更大改善(血压、血脂水平、胆固醇合成率、LDL颗粒大小和CRP)和新出现的CHD风险参数(脂肪细胞衍生的激素、体脂分布和脂肪细胞大小);以及目标3:为了确定ADMF是一种有效的饮食疗法,以维持体重减轻和冠心病风险指标的持续改善,并比较ADMF和CR受试者之间进食的认知和行为成分的变化。将实施一项为期52周的随机、对照、平行臂喂养试验来测试这些目标。试验将分为3个连续干预阶段:(1)4周基线;(2)24周体重减轻,提供食物;(3)24周体重维持,不提供食物。超重和肥胖受试者(n = 90)将随机分配至3组之一:(1)ADMF,“禁食日”限制75%能量摄入,“进食日”随意进食;(2)CR,每天限制25%能量摄入;或3)对照,每天100%能量摄入。在体重维持阶段,ADMF受试者将在“禁食日”消耗其能量需求的25%,在“进食日”消耗其能量需求的175%,而CR和对照受试者将每天消耗其能量需求的100%。我们的研究结果将表明,ADMF可以作为CR的替代方案,帮助超重和肥胖个体减肥,保持减肥效果,并持续降低CHD风险。这项研究还将深入了解ADMF发生的特定行为变化,解释为什么ADMF是维持体重的成功饮食策略。
公共卫生相关性:拟议的研究将证明隔日改良禁食(ADMF)是每日卡路里限制(CR)的合适替代方案,用于减肥,体重维持和预防心脏病。由于许多超重和肥胖的人发现很难坚持每日CR,这种饮食选择可能会提高这些饮食限制协议的依从性。反过来,这将使更大比例的超重和肥胖人群减肥,保持减肥,并防止未来发生冠心病。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Krista Amy Varady其他文献
Krista Amy Varady的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Krista Amy Varady', 18)}}的其他基金
Time restricted feeding versus daily calorie restriction: Effect on body weight, metabolic risk, and the gut microbiome
时间限制喂养与每日热量限制:对体重、代谢风险和肠道微生物组的影响
- 批准号:
10488263 - 财政年份:2021
- 资助金额:
$ 40.27万 - 项目类别:
Time restricted feeding versus daily calorie restriction: Effect on body weight, metabolic risk, and the gut microbiome
时间限制喂养与每日热量限制:对体重、代谢风险和肠道微生物组的影响
- 批准号:
10663365 - 财政年份:2021
- 资助金额:
$ 40.27万 - 项目类别:
Time restricted feeding versus daily calorie restriction: Effect on body weight, metabolic risk, and the gut microbiome
时间限制喂养与每日热量限制:对体重、代谢风险和肠道微生物组的影响
- 批准号:
10363546 - 财政年份:2021
- 资助金额:
$ 40.27万 - 项目类别:
Alternate day fasting combined with exercise for the treatment of NAFLD
隔日禁食联合运动治疗 NAFLD
- 批准号:
10411982 - 财政年份:2019
- 资助金额:
$ 40.27万 - 项目类别:
Alternate day fasting combined with exercise for the treatment of NAFLD
隔日禁食联合运动治疗 NAFLD
- 批准号:
10208879 - 财政年份:2019
- 资助金额:
$ 40.27万 - 项目类别:
Alternate day fasting combined with exercise for the treatment of NAFLD
隔日禁食联合运动治疗 NAFLD
- 批准号:
9816375 - 财政年份:2019
- 资助金额:
$ 40.27万 - 项目类别:
Alternate day fasting for weight loss, weight maintenance, and cardio-protection
隔日禁食有助于减肥、维持体重和保护心脏
- 批准号:
8270462 - 财政年份:2011
- 资助金额:
$ 40.27万 - 项目类别:
Alternate day fasting for weight loss, weight maintenance, and cardio-protection
隔日禁食有助于减肥、维持体重和保护心脏
- 批准号:
8427370 - 财政年份:2011
- 资助金额:
$ 40.27万 - 项目类别:
Alternate day fasting for weight loss, weight maintenance, and cardio-protection
隔日禁食有助于减肥、维持体重和保护心脏
- 批准号:
8605464 - 财政年份:2011
- 资助金额:
$ 40.27万 - 项目类别:
相似海外基金
I-Corps: Medication Adherence System
I-Corps:药物依从性系统
- 批准号:
2325465 - 财政年份:2023
- 资助金额:
$ 40.27万 - 项目类别:
Standard Grant
Improving Repositioning Adherence in Home Care: Supporting Pressure Injury Care and Prevention
提高家庭护理中的重新定位依从性:支持压力损伤护理和预防
- 批准号:
490105 - 财政年份:2023
- 资助金额:
$ 40.27万 - 项目类别:
Operating Grants
An innovative, AI-driven prehabilitation platform that increases adherence, enhances post-treatment outcomes by at least 50%, and provides cost savings of 95%.
%20创新、%20AI驱动%20康复%20平台%20%20增加%20依从性、%20增强%20治疗后%20结果%20by%20at%20至少%2050%、%20和%20提供%20成本%20节省%20of%2095%
- 批准号:
10057526 - 财政年份:2023
- 资助金额:
$ 40.27万 - 项目类别:
Grant for R&D
CO-LEADER: Intervention to Improve Patient-Provider Communication and Medication Adherence among Patients with Systemic Lupus Erythematosus
共同领导者:改善系统性红斑狼疮患者的医患沟通和药物依从性的干预措施
- 批准号:
10772887 - 财政年份:2023
- 资助金额:
$ 40.27万 - 项目类别:
Nuestro Sueno: Cultural Adaptation of a Couples Intervention to Improve PAP Adherence and Sleep Health Among Latino Couples with Implications for Alzheimer’s Disease Risk
Nuestro Sueno:夫妻干预措施的文化适应,以改善拉丁裔夫妇的 PAP 依从性和睡眠健康,对阿尔茨海默病风险产生影响
- 批准号:
10766947 - 财政年份:2023
- 资助金额:
$ 40.27万 - 项目类别:
Pharmacy-led Transitions of Care Intervention to Address System-Level Barriers and Improve Medication Adherence in Socioeconomically Disadvantaged Populations
药房主导的护理干预转型,以解决系统层面的障碍并提高社会经济弱势群体的药物依从性
- 批准号:
10594350 - 财政年份:2023
- 资助金额:
$ 40.27万 - 项目类别:
Unintrusive Pediatric Logging Orthotic Adherence Device: UPLOAD
非侵入式儿科记录矫形器粘附装置:上传
- 批准号:
10821172 - 财政年份:2023
- 资助金额:
$ 40.27万 - 项目类别:
Antiretroviral therapy adherence and exploratory proteomics in virally suppressed people with HIV and stroke
病毒抑制的艾滋病毒和中风患者的抗逆转录病毒治疗依从性和探索性蛋白质组学
- 批准号:
10748465 - 财政年份:2023
- 资助金额:
$ 40.27万 - 项目类别:
Improving medication adherence and disease control for patients with multimorbidity: the role of price transparency tools
提高多病患者的药物依从性和疾病控制:价格透明度工具的作用
- 批准号:
10591441 - 财政年份:2023
- 资助金额:
$ 40.27万 - 项目类别:
Development and implementation of peer-facilitated decision-making and referral support to increase uptake and adherence to HIV pre-exposure prophylaxis in African Caribbean and Black communities in Ontario
制定和实施同行协助决策和转介支持,以提高非洲加勒比地区和安大略省黑人社区对艾滋病毒暴露前预防的接受和依从性
- 批准号:
491109 - 财政年份:2023
- 资助金额:
$ 40.27万 - 项目类别:
Fellowship Programs